Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Eisai, Biogen to advance Alzheimer's drug BAN2401 in Phase III testing following failure of aducanumab

firstwordpharmaMarch 23, 2019

Tag: Biogen , Eisai , Alzheimer

PharmaSources Customer Service